Radiochemicals for research and clinical use

BV Cyclotron VU is a global health science company that produces radiopharmaceuticals and radiochemicals for medical diagnostics and research. Located at the campus of VU University Medical Center in Amsterdam, Cyclotron VU produces GMP- compliant medical isotopes in state-of-the-art manufacturing facilities.

These products are used daily by pharmaceutical and biotechnology companies, medical device manufacturers, hospitals, clinics, and research laboratories.

More information on Zirconium-89 for radiolabeling, Iodine-124 for radiolabeling, Sodium Iodide 124I for injection, 18F-Fludeoxyglucose, 18F-Fluoromethylcholine, 18F-Florbetaben (Neuraceq), KryptoScanTM: 81Rb/81mKr Generator and Type A Transport Container: Lead and Tungsten.

Do you need precise details about when and where to order your product? See our production schedule here.
Also check out our free online decay calculator!

The new state-of-the-art VUmc Imaging Center in Amsterdam

16/5/2017: The construction work on our new fully integrated, state-of-the-art imaging site is making good progress. The new building will play a crucial role in the successful and efficient development of novel diagnostic and drug therapies.arrow

PET with 89Zr-bevacizumab found promising to guide therapy in children with Diffuse Intrinsic Pontine Glioma

4/5/2017: A team of investigators from the VU University Medical Center (Amsterdam, The Netherlands) verified that the monoclonal antibody (mAb) bevacizumab, labeled with 89Zr, is able to reach tumors in children with DIPG, by quantifying its uptake by the tumors via PET.arrow

New technique uses 89Zr-radiolabelling of mixed leukocytes for PET imaging of inflammation

2/2/2017: Newly published research has assessed the radiolabeling of WBCs with 89Zr or 64Cu and their advantages for PET imaging. Radiolabeling of WBCs was more efficient with [89Zr]-loaded than with [64Cu]-loaded CN. After 2 h, [89Zr]-WBCs had an initial radioactivity loss of 28.4%, which was followed by a plateau as 89Zr remains stable in the cells. Differently, [64Cu]-WBCs had a radioactivity loss of 85% already after 1 h, which increased to 96% after 3 h.arrow

Alternative chelator for 89Zr-immuno-PET studies shows superior in vitro stability and in vivo performance

18/1/2017: 89Zr-DFO*-trastuzumab shows to be far superior to 89Zr-DFO-trastuzumab. Recent research has introduced a bifunctional isothiocyanate variant of the octadentate chelator DFO* as an alternative for DFO in 89Zr-immuno-PET. The effects of both molecules, when conjugated with the monoclonal antibody trastuzumab, were compared in vitro (stability tests) and in vivo (biodistribution in N87 tumor-bearing mice and PET imaging).arrow

In vitro and in vivo comparison of siderophores labeled with 68Ga and 89Zr

2/1/2017: 89Zr shows excellent in vitro and vivo behaviour, making it a good alternative for longitudinal PET studies of fungal infections. In an interesting publication, the in vitro, in vivo and ex vivo behavior of selected siderophores labeled with 68Ga and 89Zr have been compared, considering that the latter might constitute a radioisotope-labeling alternative for imaging of infection.arrow

High level of agreement between 124I-PET and 131I-imaging found

12/9/2016: Research from the university of Duisburg shows high level of agreement between 124I-PET and 131I-imaging. The authors conclude that pre-therapeutic 124I-PET/CT is a suitable procedure to detect iodine-positive metastases in patients with differentiated Thyroid Carcinoma. Moreover, it can be employed as a reliable tool for both staging of thyroid cancer patients as well as individualized treatment planning.arrow